Universal mammalian influenza vaccine
The present invention provides vaccine or immunogenic compositions comprising novel antigens derived from the equine strain of influenza H3N8. These proteins and specific immunogenic domains are effective as primary universal influenza antigens. The disclosed vaccines or immunogenic compositions are highly effective in inducing HA specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes. In some embodiments, the vaccine is cross-protective against two or more (e.g., 2, 3, 4, 5, or 6) subtypes of influenza with or without the use of an adjuvant.
1. A cross-protective influenza vaccine comprising:
an equine H3 antigen or immunogenic fragment thereof, wherein the equine H3 antigen comprises the amino acid sequence of SEQ ID NO: 2; and
a pharmaceutically acceptable adjuvant;
wherein the equine H3 antigen comprises at least one glycosylated residue;
wherein the vaccine targets Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276 of an equine H3 antigen head domain;
wherein antibodies generated in a subject due to immunization with the equine H3 antigen head domain bind Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276;
wherein the vaccine targets an influenza hemagglutinin head domain, wherein the vaccine is cross-protective against two or more subtypes of influenza, and wherein the vaccine is formulated for delivery via intranasal, intramuscular, subcutaneous, transdermal or sublingual administration.
2. The vaccine of claim 1 , wherein the H3 antigen is on the surface of a virus-like particle (VLP) or in secreted form.
3. The vaccine of claim 1 , wherein the vaccine is a whole inactivated virus, split viral vaccine, or live attenuated influenza vaccine.
4. The vaccine of claim 1 , wherein said adjuvant is Alum.
5. An isolated polynucleotide comprising a nucleic acid sequence encoding the equine H3 antigen of claim 1 .
6. The isolated polynucleotide of claim 5 , wherein the nucleic acid sequence encoding the equine H3 antigen is operably linked to an expression control sequence.
7. A vector comprising the nucleic acid molecule of claim 6 .
8. A cell comprising the isolated polynucleotide of claim 5 .
9. The cell of claim 8 , wherein the cell is a bacterium, insect cell, yeast cell or mammalian cell.
10. A method of vaccinating a subject for influenza comprising administering a cross-protective influenza vaccine comprising an equine H3 antigen or immunogenic fragment thereof to a subject in need thereof by intranasal, intramuscular, subcutaneous, transdermal, or sublingual administration, wherein the vaccine targets Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276 of an equine H3 antigen head domain, wherein antibodies generated in a subject due to immunization with the equine H3 antigen head domain bind Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276; wherein the equine H3 antigen comprises the amino acid sequence of SEQ ID NO: 2; and wherein the equine H3 antigen comprises at least one glycosylated residue.
11. The method of claim 10 , further comprising administering to the subject a composition comprising an influenza virus-like particle (VLP) vaccine, a whole inactivated virus, split viral vaccine, or live attenuated influenza vaccine.
12. The method of claim 11 , wherein the composition comprising influenza virus-like particle (VLP) vaccine, a whole inactivated virus, split viral vaccine, or live attenuated influenza vaccine is administered before or after the cross-protective influenza vaccine.
13. The method of claim 10 , wherein the cross-protective influenza vaccine is administered prior to influenza seasonal vaccination or after influenza seasonal vaccination.
14. The method of claim 13 , wherein the period between cross-protective influenza vaccine and seasonal vaccination administration is one day to 10 years.
15. A pharmaceutical composition comprising:
a synthetic or recombinant equine H3 polypeptide comprising multiple copies of a plurality of influenza virus peptide epitopes, wherein the equine H3 polypeptide comprises the amino acid sequence of SEQ ID NO: 2;
at least one seasonal or pandemic preparation against influenza; and
a pharmaceutically acceptable adjuvant;
wherein the equine H3 antigen comprises at least one glycosylated residue;
wherein the pharmaceutical composition targets Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276 of an equine H3 polypeptide head domain;
wherein antibodies generated in a subject due to immunization with the equine H3 polypeptide head domain bind Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276; and
wherein the pharmaceutical composition is formulated for delivery via intranasal, intramuscular, subcutaneous, transdermal or sublingual administration and is cross-protective against two or more subtypes of influenza.
16. A method for inducing an immune response or conferring protection against influenza in a subject, wherein the method comprises administering to the subject a pharmaceutical composition according to claim 15 .
17. An immunogenic composition comprising:
a recombinant or synthesized equine H3 antigen or immunogenic fragment thereof, wherein the equine H3 antigen comprises the amino acid sequence of SEQ ID NO: 2; and
a pharmaceutically acceptable adjuvant;
wherein the equine H3 antigen comprises at least one glycosylated residue;
wherein the composition targets Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276 of an equine H3 antigen head domain;
wherein antibodies generated in a subject due to immunization with the equine H3 antigen head domain bind Asn204, Ala153, Asn111, Asn187, Met275, and/or Arg276; and
wherein the composition is formulated to have increased solubility and is cross-protective against two or more subtypes of influenza.
18. The immunogenic composition of claim 17 , further comprising a pharmaceutically acceptable carrier.
19. A method for generating an immune response to two or more influenza hemagglutinin subtypes and/or influenza types, comprising administering to a subject an effective amount of the immunogenic composition of claim 17 , thereby generating the immune response.
20. The method of claim 19 , wherein said subject is a mammal.
21. The method of claim 19 , wherein said mammal is a human.
22. The method of claim 19 , wherein said mammal is a porcine.